Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Advancements in Polymer and Lipid-based Nanotherapeutics for Cancer Drug Targeting

Author(s): Mohammed Asadullah Jahangir, Mohamad Taleuzzaman*, Chandra Kala and Sadaf Jamal Gilani

Volume 26, Issue 40, 2020

Page: [5119 - 5127] Pages: 9

DOI: 10.2174/1381612826999200820173253

Price: $65

Abstract

Cancer is a global disease. It is the second leading cause of death worldwide, according to the health report. Approximately 70% of deaths from cancer occurs in low- and middle-income countries. According to the WHO, in 2015 8.8 million deaths were reported due to cancer worldwide. The conventional system of medicine was used since a long for the management of the disease, but it comes with the drawback of low safety, less efficacy and non-targeting of cancer cells. Nanotherapeutics has become the most exploited drug targeting system based on the safety and efficacy this system provides over the conventional system. This review summarizes an advanced design consideration in anticancer therapy, recent advancements in the nanocarrier-based advanced drug targeting, challenges and limitations related to nanoparticles-based therapy in cancer and its future perspective. The review also lists the on-going clinical trials in the last five years on nano-based therapy for different types of cancer. The data for this article was obtained by an extensive literature review of related published scientific contents from the WHO’s website, PubMed, Scopus, Scielo, clinicaltrials.gov and other relevant scientific archiving services. The safety and efficacy that nanoparticles provide, and the current research strongly support their application in cancer drug targeting. However, their presence in the market is still limited. Nanotherapeutics in cancer drug targeting needs extensive research in association with pharmaceutical industries. Nano-targeting based therapies are the future of pharmaceutical designing for the diagnosis, management and prevention of different forms of cancer.

Keywords: Nanotherapeutics, cancer drug targeting, lipid-based nanoparticles, polymer-based nanoparticles, anticancer therapy, diagnosis.

« Previous Next »
[1]
World Health Organization. Status of the health-related SDGs 2017.
[2]
Monitoring Health for the SDGs. Lyon, France: World Health Organization 2017; 29-35.
[3]
Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv Drug Deliv Rev 2010; 62(2): 203-30.
[http://dx.doi.org/10.1016/j.addr.2009.11.028] [PMID: 19951732]
[4]
Jäger E, Jäger A, Etrych T, et al. ˇRíhová B, Ulbrich K, Štˇepánek P, Self-assembly of biodegradable copolyester and reactive HPMA-basedpolymers into nanoparticles as an alternative stealth drug delivery system. Soft Matter 2012; 8: 9563-75.
[http://dx.doi.org/10.1039/c2sm26150b]
[5]
Alsuraifi A, Curtis A, Lamprou DA, Hoskins C. Stimuli responsive polymeric systems for cancer therapy. Pharmaceutics 2018; 10(3): 1-17.
[http://dx.doi.org/10.3390/pharmaceutics10030136] [PMID: 30131473]
[6]
Kshirsagar NA. Drug delivery systems. Indian J Pharmacol 2000; 32: 54-61.
[7]
Teja SB, Patil SP, Shete G, Patel S, Bansal AK. Drug-excipient behaviour in polymeric amorphous solid dispersions. J Excip Food Chem 2013; 4: 70-94.
[8]
Swamy MK, Sinniah UR. Patchouli (Pogostemon cablin Benth.): botany, agrotechnology and biotechnological aspects. Ind Crops Prod 2016; 87: 161-76.
[http://dx.doi.org/10.1016/j.indcrop.2016.04.032]
[9]
Mohanty SK, Swamy MK, Sinniah UR, Anuradha M. Leptadenia reticulata (Retz.) Wight & Arn. (Jivanti): botanical, agronomical, phytochemical, pharmacological, and biotechnological aspects. Molecules 2017; 22(6): 1-27.
[http://dx.doi.org/10.3390/molecules22061019] [PMID: 28629185]
[10]
Shah PA, Shelat P, Dave D, Shah G. Advancement in polymer therapeutics and characterization Asian. J Pharm 2009; 3(3)
[http://dx.doi.org/10.4103/0973-8398.56297]
[11]
Chilkoti A, Dreher MR, Meyer DE, Raucher D. Targeted drug delivery by thermally responsive polymers. Adv Drug Deliv Rev 2002; 54(5): 613-30.
[http://dx.doi.org/10.1016/S0169-409X(02)00041-8] [PMID: 12204595]
[12]
Kwon YM, Kim SW. Thermo sensitive biodegradable hydrogels for the delivery of therapeutic agents, polymeric drug delivery systems. Taylor and Francis Group 2005; 148: 265-70.
[13]
Kikuchi A, Okano T. Hydrogels-stimuli-sensitive hydrogels, polymeric drug delivery systems. Taylor and Francis Group 2005; 148: 309-12.
[14]
Akhter MH, Rizwanullah M, Ahmad J, Ahsan MJ, Mujtaba MA, Amin S. Nanocarriers in advanced drug targeting: setting novel paradigm in cancer therapeutics. Artif Cells Nanomed Biotechnol 2018; 46(5): 873-84.
[http://dx.doi.org/10.1080/21691401.2017.1366333] [PMID: 28830262]
[15]
Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004; 10(24): 2981-9.
[http://dx.doi.org/10.2174/1381612043383467] [PMID: 15379663]
[16]
Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng 2010; 1: 149-73.
[http://dx.doi.org/10.1146/annurev-chembioeng-073009-100847] [PMID: 22432577]
[17]
Rowe RC, Sheskey PJ, Owen SC. Handbook of Pharmaceutical Excipients. In: 5th ed Grayslake, IL: Washington, DC: Pharmaceutical Press; American Pharmacists Association. 2005; 850.
[18]
Langer RS, Peppas NA. Present and future applications of biomaterials in controlled drug delivery systems. Biomaterials 1981; 2(4): 201-14.
[http://dx.doi.org/10.1016/0142-9612(81)90059-4] [PMID: 7034798]
[19]
Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm 2000; 26(7): 695-708.
[http://dx.doi.org/10.1081/DDC-100101287] [PMID: 10872087]
[20]
Gil ES, Hudson SA. Stimuli-reponsive polymers and their bioconjugates. Prog Polym Sci 2004; 29(12): 1173-222.
[http://dx.doi.org/10.1016/j.progpolymsci.2004.08.003]
[21]
Schmaljohann D. Thermo- and pH-responsive polymers in drug delivery. Adv Drug Deliv Rev 2006; 58(15): 1655-70.
[http://dx.doi.org/10.1016/j.addr.2006.09.020] [PMID: 17125884]
[22]
Schild HG. Poly (N-isopropylacrylamide): experiment, theory and application. Prog Polym Sci 1992; 17(2): 163-249.
[http://dx.doi.org/10.1016/0079-6700(92)90023-R]
[23]
Khare AR, Peppas NA. Swelling/deswelling of anionic copolymer gels. Biomaterials 1995; 16(7): 559-67.
[http://dx.doi.org/10.1016/0142-9612(95)91130-Q] [PMID: 7492721]
[24]
Malmsten M, Lindman B. Self-assembly in aqueous block copolymer solutions. Macromolecules 1992; 25(20): 5440-5.
[http://dx.doi.org/10.1021/ma00046a049]
[25]
Topp MDC, Jijkstra PJ, Talsma H, Feijen J. Thermosensitive micelle-forming block copolymers of poly (ethylene glycol) and poly (N-isopropylacrylamide). Macromolecules 1997; 30(26): 8518-20.
[http://dx.doi.org/10.1021/ma9710803]
[26]
Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med 2017; 6(1): 44.
[http://dx.doi.org/10.1186/s40169-017-0175-0] [PMID: 29230567]
[27]
Parveen R, Ahmad FJ, Iqbal Z, Samim M, Ahmad S. Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug Dev Ind Pharm 2014; 40(9): 1206-12.
[http://dx.doi.org/10.3109/03639045.2013.810636] [PMID: 23826860]
[28]
Bae Y, Nishiyama N, Kataoka K. In vivo antitumor activity of the folate-conjugated pH-sensitive polymeric micelle selectively releasing adriamycin in the intracellular acidic compartments. Bioconjug Chem 2007; 18(4): 1131-9.
[http://dx.doi.org/10.1021/bc060401p] [PMID: 17488066]
[29]
Gad A, Kydd J, Piel B, Rai P. Targeting cancer using polymeric nanoparticle mediated combination chemotherapy. Int J Nanomed Nanosurg 2016; 2(3)
[PMID: 28042613]
[30]
Anselmo AC, Mitragotri S. A review of clinical translation of inorganic nanoparticles. AAPS J 2015; 17(5): 1041-54.
[http://dx.doi.org/10.1208/s12248-015-9780-2] [PMID: 25956384]
[31]
NCI Drug Dictionary. spherical nucleic acid nanoparticle NU-0129 Available from: https://www.cancer.gov/publications/dictionaries/cancer
[32]
Liu Y, Zhang P, Li F, et al. Metal-based NanoEnhancers for future radiotherapy: Radiosensitizing and synergistic effects on tumor cells. Theranostics 2018; 8(7): 1824-49.
[http://dx.doi.org/10.7150/thno.22172] [PMID: 29556359]
[33]
Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006; 6(9): 688-701.
[http://dx.doi.org/10.1038/nrc1958] [PMID: 16900224]
[34]
Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomedicine 2017; 12: 7291-309.
[http://dx.doi.org/10.2147/IJN.S146315] [PMID: 29042776]
[35]
Wacker M. Nanocarriers for intravenous injection--the long hard road to the market. Int J Pharm 2013; 457(1): 50-62.
[http://dx.doi.org/10.1016/j.ijpharm.2013.08.079] [PMID: 24036012]
[36]
Lasic DD. A molecular model for vesicle formation. Biochim Biophys Acta 1982; 692(3): 501-2.
[http://dx.doi.org/10.1016/0005-2736(82)90404-7] [PMID: 7171607]
[37]
Nickels J, Palmer AF. Changes in liposome morphology induced by actin polymerization in submicrometer liposomes. Langmuir 2003; 19: 10581-7.
[http://dx.doi.org/10.1021/la035114d]
[38]
Jores K, Mehnert W, Drechsler M, Bunjes H, Johann C, Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 2004; 95(2): 217-27.
[http://dx.doi.org/10.1016/j.jconrel.2003.11.012] [PMID: 14980770]
[39]
Hasan W, Chu K, Gullapalli A, et al. Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer. Nano Lett 2012; 12(1): 287-92.
[http://dx.doi.org/10.1021/nl2035354] [PMID: 22165988]
[40]
Wang J, Byrne JD, Napier ME, DeSimone JM. More effective nanomedicines through particle design. Small 2011; 7(14): 1919-31.
[http://dx.doi.org/10.1002/smll.201100442] [PMID: 21695781]
[41]
Jores K, Haberland A, Wartewig S, Mäder K, Mehnert W. Solid lipid nanoparticles (SLN) and oil-loaded SLN studied by spectrofluorometry and Raman spectroscopy. Pharm Res 2005; 22(11): 1887-97.
[http://dx.doi.org/10.1007/s11095-005-7148-5] [PMID: 16132349]
[42]
Pignatello R, Musumeci T, Graziano AC, et al. A study on liposomal encapsulation of a lipophilic prodrug of LHRH. Pharm Dev Technol 2015; 21(6): 664-71.
[http://dx.doi.org/10.3109/10837450.2015.1041045] [PMID: 25946073]
[43]
Tayebi L, Vashaee D, Parikh AN. Stability of uni- and multillamellar spherical vesicles. ChemPhysChem 2012; 13(1): 314-22.
[http://dx.doi.org/10.1002/cphc.201100573] [PMID: 22012854]
[44]
Porter CJ, Moghimi SM, Illum L, Davis SS. The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow. FEBS Lett 1992; 305(1): 62-6.
[http://dx.doi.org/10.1016/0014-5793(92)80655-Z] [PMID: 1633861]
[45]
Daemen T, Velinova M, Regts J, et al. Different intrahepatic distribution of phosphatidylglycerol and phosphatidylserine liposomes in the rat. Hepatology 1997; 26(2): 416-23.
[http://dx.doi.org/10.1002/hep.510260223] [PMID: 9252153]
[46]
Nagayasu A, Uchiyama K, Kiwada H. The size of liposomes: a factor which affects their targeting efficiency to tumors and therapeutic activity of liposomal antitumor drugs. Adv Drug Deliv Rev 1999; 40(1-2): 75-87.
[http://dx.doi.org/10.1016/S0169-409X(99)00041-1] [PMID: 10837781]
[47]
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7(9): 771-82.
[http://dx.doi.org/10.1038/nrd2614] [PMID: 18758474]
[48]
Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154: 123-40.
[http://dx.doi.org/10.1016/S0378-5173(97)00135-X]
[49]
Sabín J, Prieto G, Ruso JM, et al. Interactions between DMPC liposomes and the serum blood proteins HSA and IgG. J Phys Chem B 2009; 113(6): 1655-61.
[http://dx.doi.org/10.1021/jp804641e] [PMID: 19159271]
[50]
Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148(2): 135-46.
[http://dx.doi.org/10.1016/j.jconrel.2010.08.027] [PMID: 20797419]
[51]
Ganta S, Devalapally H, Shahiwala A, Amiji M. A review of stimuli-responsive nanocarriers for drug and gene delivery. J Control Release 2008; 126(3): 187-204.
[http://dx.doi.org/10.1016/j.jconrel.2007.12.017] [PMID: 18261822]
[52]
Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008; 14(5): 1310-6.
[http://dx.doi.org/10.1158/1078-0432.CCR-07-1441] [PMID: 18316549]
[53]
Wu S-C, Yu C-H, Lin C-W, Chu I-M. The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 2003; 21(19-20): 2516-22.
[http://dx.doi.org/10.1016/S0264-410X(03)00042-2] [PMID: 12744886]
[54]
Xin Y, Yin M, Zhao L, Meng F, Luo L. Recent progress on nanoparticle-based drug delivery systems for cancer therapy. Cancer Biol Med 2017; 14(3): 228-41.
[http://dx.doi.org/10.20892/j.issn.2095-3941.2017.0052] [PMID: 28884040]
[55]
Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res 2012; 72(21): 5566-75.
[http://dx.doi.org/10.1158/0008-5472.CAN-12-1683] [PMID: 22952218]
[56]
Crist R, McNeil S. Nanotechnology for treating cancer: pitfalls and bridges on the path to nanomedicines. National cancer institute 2015.
[57]
Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: Strategies to enhance patient responses. Adv Drug Deliv Rev 2018; 130: 17-38.
[http://dx.doi.org/10.1016/j.addr.2018.07.007] [PMID: 30009886]
[58]
Zhang B, Hu Y, Pang Z. Modulating the tumor microenvironment to enhance tumor nanomedicine delivery. Front Pharmacol 2017; 8: 952.
[http://dx.doi.org/10.3389/fphar.2017.00952] [PMID: 29311946]
[59]
Bostan HB, Rezaee R, Valokala MG, et al. Cardiotoxicity of nano-particles. Life Sci 2016; 165: 91-9.
[http://dx.doi.org/10.1016/j.lfs.2016.09.017] [PMID: 27686832]
[60]
Duan J, Yu Y, Li Y, Yu Y, Sun Z. Cardiovascular toxicity evaluation of silica nanoparticles in endothelial cells and zebrafish model. Biomaterials 2013; 34(23): 5853-62.
[http://dx.doi.org/10.1016/j.biomaterials.2013.04.032] [PMID: 23663927]
[61]
Park K. Facing the truth about nanotechnology in drug delivery. ACS Nano 2013; 7(9): 7442-7.
[http://dx.doi.org/10.1021/nn404501g] [PMID: 24490875]
[62]
Sukhanova A, Bozrova S, Sokolov P, Berestovoy M, Karaulov A, Nabiev I. Dependence of nanoparticle toxicity on their physical and chemical properties. Nanoscale Res Lett 2018; 13(1): 44.
[http://dx.doi.org/10.1186/s11671-018-2457-x] [PMID: 29417375]
[63]
Shubhika K. Nanotechnology and medicine - The upside and the downside. Int J Drug Dev & Res 2013; 5(1): 1-10.
[64]
Ankamwar B. Size and shape effect on biomedical applications of nanomaterialsbiomedical engineering. Technical Applications in Medicine 2012.
[65]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[66]
Faunce TA. Nanotherapeutics: new challenges for safety and cost-effectiveness regulation in Australia. Med J Aust 2007; 186(4): 189-91.
[http://dx.doi.org/10.5694/j.1326-5377.2007.tb00860.x] [PMID: 17309421]
[67]
Australian Safety. Compensation Council, A Review of the Potential Occupational Health and Safety Implications of Nanotechnology Report for the Department of Employment and Workplace Relations. Adelaide: Flinders Consulting 2006.
[68]
Xia T, Kovochich M, Brant J, et al. Comparison of the abilities of ambient and manufactured nanoparticles to induce cellular toxicity according to an oxidative stress paradigm. Nano Lett 2006; 6(8): 1794-807.
[http://dx.doi.org/10.1021/nl061025k] [PMID: 16895376]
[69]
Lademann J, Weigmann H, Rickmeyer C, et al. A review of the scientific literature on the safety of nanoparticulate titanium dioxide or zinc oxide in sunscreens. Australian Government 2006.
[70]
Nyström AM, Fadeel B. Safety assessment of nanomaterials: implications for nanomedicine. J Control Release 2012; 161(2): 403-8.
[http://dx.doi.org/10.1016/j.jconrel.2012.01.027] [PMID: 22306428]
[71]
Penn A, Murphy G, Barker S, Henk W, Penn L. Combustion-derived ultrafine particles transport organic toxicants to target respiratory cells. Environ Health Perspect 2005; 113(8): 956-63.
[http://dx.doi.org/10.1289/ehp.7661] [PMID: 16079063]
[72]
Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomedicine 2018; 13: 3921-35.
[http://dx.doi.org/10.2147/IJN.S165210] [PMID: 30013345]
[73]
Khan A, Aqil M, Imam SS, et al. Temozolomide loaded nano lipid based chitosan hydrogel for nose to brain delivery: Characterization, nasal absorption, histopathology and cell line study. Int J Biol Macromol 2018; 116: 1260-7.
[http://dx.doi.org/10.1016/j.ijbiomac.2018.05.079] [PMID: 29775717]
[74]
Khan A, Imam SS, Aqil M, et al. Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Mol Pharm 2016; 13(11): 3773-82.
[http://dx.doi.org/10.1021/acs.molpharmaceut.6b00586] [PMID: 27661966]
[75]
Khan K, Aqil M, Imam SS, et al. Ursolic acid loaded intra nasal nano lipid vesicles for brain tumour: Formulation, optimization, in-vivo brain/plasma distribution study and histopathological assessment. Biomed Pharmacother 2018; 106: 1578-85.
[http://dx.doi.org/10.1016/j.biopha.2018.07.127] [PMID: 30119233]
[76]
Mishra J, Panda JJ. Short peptide-based smart targeted cancer nanotherapeutics: a glimmer of hope. Ther Deliv 2019; 10(3): 135-8.
[http://dx.doi.org/10.4155/tde-2019-0005] [PMID: 30909857]
[77]
Singh VK, Saini A, Chandra R. The implications and future perspectives of nanomedicine for cancer stem cell targeted therapies. Front Mol Biosci 2017; 4: 52.
[http://dx.doi.org/10.3389/fmolb.2017.00052] [PMID: 28785557]
[78]
Qiao Y, Wan J, Zhou L, et al. Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2019; 11(1)e1527
[http://dx.doi.org/10.1002/wnan.1527] [PMID: 29726115]
[79]
Mansinho A, Boni V, de Miguel M, Calvo E. The future of oncology therapeutics. Expert Rev Anticancer Ther 2017; 17(7): 563-5.
[http://dx.doi.org/10.1080/14737140.2017.1331131] [PMID: 28504011]
[80]
Available at: https://clinicaltrials.gov/2019

Rights & Permissions Print Cite
Article Metrics
11
2
© 2024 Bentham Science Publishers | Privacy Policy